Alnylam Pharmaceuticals vs Biomarin Pharmaceutical
Alnylam Pharmaceuticals is the larger business, with $3.71bn of revenue in fiscal 2025 against $3.22bn for Biomarin Pharmaceutical (1.2 times as much). Alnylam Pharmaceuticals grew faster (65.2% against 12.9%). Biomarin Pharmaceutical kept more of each dollar of sales as profit: a net margin of 10.8% against 8.4%. Biomarin Pharmaceutical carries less debt relative to equity (9.9% against 127.7%).
| Latest fiscal year | Alnylam PharmaceuticalsALNY, 2025 | Biomarin PharmaceuticalBMRN, 2025 |
|---|---|---|
| Revenue | $3.71bn | $3.22bn |
| Revenue growth | 65.2% | 12.9% |
| Net income | $314m | $349m |
| Operating margin | 13.5% | 12.7% |
| Net margin | 8.4% | 10.8% |
| Return on equity | 73.3% | 5.9% |
| Free cash flow | $465m | $725m |
| Cash | $1.66bn | $1.31bn |
| Total debt | $1.01bn | $600m |
| Debt to equity | 127.7% | 9.9% |
| Dividend per share | — | — |
| Dividend yield | — | — |
| Share buybacks | — | — |
| Employees | 2,500 | 3,221 |
| Market value | $21.46bn | $10.80bn |
| Price vs our value range | Above our value range | Within our value range |
| Moat score | 33 (Weak) | 40 (Weak) |
| Insider trades, 12 months | 0 buys, 279 sales | 0 buys, 5 sales |